People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
In an article published online inJAMA Internal Medicine, the scientists say the new drugs -- glucagon-like peptide-1-based therapies (GLP-1) -- are associated with an increased risk of hospitalization for acute pancreatitis. The agents sitagliptin and exenatide -- generic names for the drugs sold under the brand names Januvia and Byetta -- appear to contribute to the formation of lesions in the pancreas and the proliferation of ducts in the organ, resulting in wellsprings of inflammation.
"These agents are used by millions of Americans with diabetes. These new diabetes drugs are very effective in lowering blood glucose. However, important safety findings may not have been fully explored and some side effects such as acute pancreatitis don't appear until widespread use after approval," says study leader Sonal Singh, M.D., M.P.H., an assistant professor in the Division of General Internal Medicine at the Johns Hopkins University School of Medicine.
Full story here.
Please check out our website www.lowcarbdiabetic.co.uk We created and maintain this site without any help from anyone else. In doing so, we do not receive direct or indirect funding from anyone. We do not accept money or favours to manipulate the evidence in any way. Please visit our Low Carb food and recipe blog www.lowcarbdietsandrecipes.blogspot.com
3 comments:
Care and good research needed for any drug, recommended read
Jeff
"People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis,"
Extremely worrying...
I do think that as years have passed the way drugs are tested and the time allowed for testing is far too short. As I am not a scientist or researcher I am not sure of the length of time we should allow for proper and full testing to take place, but I feel that many drugs these days are not being tested fully.
A layman's point of view but that's how I feel about it.
Jean
Having seen the problems with Avandia and Actos, I can't say I'm surprised that more drugs are being shown to put diabetics at risk.
Hope Warshaw said in her State of the Nutrient article:
We've come along way baby, as the saying goes, with BG lowering medications.
Nuff said
Graham
Post a Comment